Targeting the cytotoxic T lymphocyte- associated protein-4 (CTLA-4), programed cell death protein-1 (PD-1) or programed death ligand-1 (PD-L1) by inhibitory antibodies is approved for various cancer types including NSCLC and RCC. This evidence concerns the gene PDCD1 and cancer.